Dos Reis Samuel Roosevelt Campos, Quixadá Acy Telles de Souza, Nunes Sammara Tavares, Cid Danielle Maria Camelo, de Souza Jacqueline Holanda, da Costa Clara Maria Bastos Eloy, Silveira Carolina Bizelli, Cid David Antonio Camelo, de Oliveira Mariana Fátima Cabral
Universidade Federal do Ceará, UFC, Fortaleza, CE, Brazil.
Rev Bras Hematol Hemoter. 2013;35(3):174-9. doi: 10.5581/1516-8484.20130053.
The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia.
A retrospective review was performed of 100 non-electronic records of patients with Ph(+) chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package.
At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response.
The population of this study obtained lower-than-expected therapeutic responses compared to other studies.
本研究旨在确定慢性髓性白血病患者甲磺酸伊马替尼治疗依从性失败的原因。
对100例接受甲磺酸伊马替尼治疗的Ph(+)慢性髓性白血病患者的非电子病历进行回顾性研究。研究期间为2001年1月至2011年1月。使用统计分析系统软件包通过卡方检验和对应分析对数据进行分析。
治疗开始时，41%的患者处于疾病晚期。药物不可用（44.8%）和骨髓毒性（25.7%）是最常见的中断原因。47%的病例依从率<90%。低依从性影响细胞遗传学反应（p值=0.020）和分子反应（p值=0.001）。非常高的依从性（>95%）可诱导完全细胞遗传学反应、主要细胞遗传学反应和主要分子反应。
与其他研究相比，本研究人群获得的治疗反应低于预期。
